U.S FDA approves CERA-CHEK 1070 Blood Glucose Monitoring System 


Ceragem Medisys announced that the United States Food and Drug Administration (FDA) approved the CERA-CHEK 1070, its Blood Glucose Monitoring System. 

The blood glucose monitor manufacturer under Ceragem Group, a leading manufacturer of thermal massage beds, developed the model for children suffering from diabetes. 

Most of these are type 1 diabetes, having to be given insulin for their whole life. Ceragem Medisys explained that it focused on a technology that allows customers check the level of glucose in their blood within 5 seconds and with only 0.5 micro-liter of blood, without hematocrit effect in blood checking. 

The product features a side-grip strip in order to minimize blood contact and prevent possible infection during the self-screening of hemoglobin level.

"The approval from the FDA is an important first step for us to advance into the United States, the biggest diabetes market ... We will increase our market share by developing diverse channels and forming strategic OEM business ties," said Lee Jin-woo, CEO of the company. 

    • English
    • Korean
  • menu1
  • menu2
  • menu3
  • menu4
  • menu5
  • menu6